Nature and BioCentury have announced SciBX, a new publication that will distill and analyse newly published life science research, aiding the translation of academic science into commercial products
The preview edition of SciBX (science-business exchange) was shown at the JPMorgan healthcare conference in San Francisco this week.
The electronic publication will be distributed to SciBX subscribers every Thursday, starting 31 January 2008.
The companies also announced a website featuring a free preview edition of SciBX and information on the publication and charter subscription rates.
"SciBX will provide a unique service to the biopharma industry," said Peter Collins, publishing director for Nature Publishing.
"There are no two partners better suited to bring forth such a novel publication, given our respective areas of expertise".
SciBX will evaluate hundreds of high impact peer-reviewed scientific articles every week and pick the most commercially relevant findings that merit deeper analysis.
This multidisciplinary approach will provide scientific context, identify potential commercial impact and describe the next steps required to translate the newest developments in the lab into innovative healthcare solutions.
"We expect SciBX to fill the crucial translational gap," said David Flores, co-founder, president and CEO of BioCentury.
"Our goal is to combine the skills of BioCentury and Nature Publishing to improve the speed and efficiency with which commercially relevant new science is identified, funded and partnered".
The biopharmaceutical industry and its investors are inundated with complex scientific papers describing the latest discoveries each week.
According to Medline, over 600,000 articles were added to its database in 2006 alone.
SciBX will help distill this flood of scientific data by filtering and analysing key findings within the most current scientific and business context.
It will be an indispensable resource for biotechnology and pharmaceutical executives, business development specialists, drug discovery and development teams, venture capitalists and other investment professionals who wish to identify new projects and potential new partners, to find enabling technology and scan their environment for disruptive competitive advances.
